化学信息：
| 中文名 | 人参皂苷Re |
| 英文名 | Ginsenoside Re |
| 中文别名 | - |
| 英文别名 | Ginsenoside B2; Panaxoside Re; Sanchinoside Re |
| 来源 | 人参Panax ginseng C. A. Meyer |
| 化合物类型 | 萜类(Terpenoids)>三萜>达玛烷型四环三萜皂苷 |
| 化学式 | C48H82O18 |
| 分子量 | 947.15 |
| CAS号 | 52286-59-6 |
| 纯度 | 98%, HPLC |
| 溶剂/溶解度 | DMSO: ≥ 50 mg/ml (52.79 mM) |
| 溶液配制 | 10mg加入1.06ml DMSO，或者每9.47mg加入1ml DMSO，配制成10mM溶液。 |
生物信息
| 产品描述 | Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the β-amyloid protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB. | ||||
| 信号通路 | - | ||||
| 靶点 | NF-κB | JNK | Aβ | - | - |
| IC50 | - | - | - | - | - |
| 体外研究 | Ginsenoside Re is a well-known traditional Chinese medicine, which decreases the β-site amyloid precursor protein cleaving enzyme 1 (BACE1) mRNA and protein levels and inhibits BACE1 activity in the N2a/APP695 cells. Ginsenoside Re also significantly increases the PPARγ protein and mRNA levels.To prevent Ginsenoside Re from having a cytotoxic effect on the N2a/APP695 cells, the cell viability is first determined by the MTT assay. The N2a/WT and N2a/APP695 cells are treated with increasing concentrations of Ginsenoside Re (0-200 µM) for 24 h. Ginsenoside Re concentrations under 100 µM do not affect the viability of the N2a/WT and N2a/APP695 cells, whereas the 150 µM Ginsenoside Re concentration markedly decreases the survival rate of the N2a/WT and N2a/APP695 cells. Incubation with Ginsenoside Re at a 200 µM concentration for 24 h reduces the viability of the N2a/WT and N2a/APP695 cells by 15.58% and 26.82%, respectively. These data indicate that Ginsenoside Re treatment within the range of 0-100 µM for 24 h is safe for the N2a/WT and N2a/APP695 cells (P>0.05). | ||||
| 体内研究 | Ginsenoside Re reduces insulin resistance in 3T3-L1 adipocytes and high-fat diet (HFD) rats through inhibition of JNK and NF-κB activation. Intraperitoneal injection of lipopolysaccharide (LPS) at a dose of 20 mg/kg is lethal to mice, and 70% to 80% of the mice die within 60 h. However, pretreatment of the mice with Rg1 or Ginsenoside Re increases their survival rates in a dose-dependent manner. With the doses of Rg1 or Ginsenoside Re increase from 2.5 to 5 mg/kg, the survival rate is elevated from 60% to 90% (Rg1) or from 30% to 40% (Ginsenoside Re). All the mice administered Rg1 at a minimal dose of 10 mg/kg are protected from death compared to 80% survival of mice treated with an equal dose of Ginsenoside Re. To protect all the mice, 20 mg/kg Ginsenoside Re is needed. To investigate the anti-inflammatory potential of Rg1 and Ginsenoside Re, 1 mg/kg Rg1 or Ginsenoside Re is injected into rats and then challenged the animals with LPS. The injection procedure itself causes a transient stress-induced increase in body temperature of ~1.2°C in each group. Thereafter, LPS-challenged rats without pretreatment develope a robust biphasic fever, with the first peak reaching ~1.5°C at 2 h and the second peak reaching 1.8°C at 4 h. In contrast, the temperature changes for the Rg1-, Ginsenoside Re-, and TAK-242-treated groups are only 0.9, 1.2, and 0.8°C at 2 h and 1.3, 1.4, and 1.0°C at 4 h, respectively. Pretreatment with Rg1, Ginsenoside Re, or TAK-242 significantly attenuates LPS-induced alterations in body temperature. | ||||
| 临床实验 | NCT00781534: Diabetes, Early Phase 1. | ||||
1. Cao G, et al. Eur J Pharmacol. 2016,793:101-108.
2. Su F, et al. Antimicrob Agents Chemother. 2015,59(9):5654-63.
3. Zhang Z, et al. Mol Endocrinol. 2008,22(1):186-95.
包装清单：| 产品编号 | 产品名称 | 包装 |
| SM6036-10mM | 人参皂苷Re (98%, HPLC) | 10mM×0.2ml |
| SM6036-25mg | 人参皂苷Re (98%, HPLC) | 25mg |
| SM6036-100mg | 人参皂苷Re (98%, HPLC) | 100mg |
| - | 说明书 | 1份 |
-20℃保存，至少一年有效。固体粉末4℃保存，至少一个月有效。如果溶于非DMSO溶剂，建议分装后-80℃保存，预计6个月内有效。
注意事项：本产品可能对人体有一定的毒害作用，请注意适当防护，以避免直接接触人体或吸入体内。
本产品仅限于专业人员的科学研究用，不得用于临床诊断或治疗，不得用于食品或药品，不得存放于普通住宅内。
为了您的安全和健康，请穿实验服并戴一次性手套操作。
